Analysts Offer Predictions for NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTRFree Report) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings per share of ($0.17) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.79) EPS.

A number of other equities research analysts have also recently issued reports on NKTR. Piper Sandler began coverage on Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.10.

Read Our Latest Stock Report on NKTR

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $1.02 on Wednesday. Nektar Therapeutics has a one year low of $0.46 and a one year high of $1.93. The company has a market cap of $188.15 million, a price-to-earnings ratio of -1.21 and a beta of 0.57. The firm has a 50-day moving average of $1.23 and a 200-day moving average of $1.25.

Institutional Trading of Nektar Therapeutics

Several large investors have recently modified their holdings of NKTR. Barclays PLC grew its holdings in shares of Nektar Therapeutics by 96.1% during the 3rd quarter. Barclays PLC now owns 358,294 shares of the biopharmaceutical company’s stock valued at $466,000 after purchasing an additional 175,596 shares during the last quarter. XTX Topco Ltd bought a new stake in Nektar Therapeutics in the third quarter valued at approximately $46,000. Jane Street Group LLC increased its position in shares of Nektar Therapeutics by 50.0% during the third quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 30,481 shares during the period. Wellington Management Group LLP acquired a new stake in Nektar Therapeutics during the 3rd quarter worth about $615,000. Finally, State Street Corp grew its stake in Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after purchasing an additional 355,759 shares during the period. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

Featured Articles

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.